Key result
Reductive annuloplasty of mitral and tricuspid valves during CABG in patients with ischemic dilated cardiomyopathy resulted in a 30-day mortality of 7.5% and a 10-year survival rate of 38.05%.
Why the study?
Does reductive annuloplasty of mitral and tricuspid valves at the time of CABG improve survival in patients with end-stage ischemic dilated cardiomyopathy?
Cohort (n=226)
Does reductive annuloplasty of mitral and tricuspid valves at the time of CABG improve survival in patients with end-stage ischemic dilated cardiomyopathy?
Reductive annuloplasty of mitral and tricuspid valves during CABG is a feasible alternative to heart transplantation in selected patients with end-stage ischemic dilated cardiomyopathy, offering acceptable long-term survival.
Supports combined annuloplasty with CABG as feasible in selected ischemic cardiomyopathy; leaves open randomized confirmation of survival benefit versus alternatives.
OBJECTIVE: Patients with ischemic dilated cardiomyopathy exhibit extensive remodeling of the left ventricle, annular dilation, and significant mitral and tricuspid regurgitation. These changes increase per operative morbidity and mortality, and emphasize patient candidacy for heart transplantation. The aim of this study is to show immediate and long-term results after reductive annuloplasty of double (mitral and tricuspid) orifices, performed at the time of coronary artery bypass grafting, as an alternative to heart transplantation. METHODS: There were 226 consecutive patients (205 males, 21 females) with ischemic dilated cardiomyopathy, mean ejection fraction below 30% [(26.6 +/- 3.1)%], and mean left ventricle end-diastolic internal diameter greater than 7.0 cm (7.3 +/- 0.3 cm). In addition to myocardial revascularization, Carpentier's mitral annuloplasty and posterior semicircular reductive annuloplasty were performed in 37 and 189 patients, respectively. In all 226 patients, a modified De Vega's tricuspid annuloplasty was performed. RESULTS: Postoperative 30-day mortality was 7.5% (17 patients). Survival rates after 5 and 10 years were (61.5 +/- 4.0)% and (38.05 +/- 8.0)%, respectively. CONCLUSION: Reductive annuloplasty of mitral and tricuspid orifices performed at the time of myocardial revascularization could be beneficial in selective patients with ischemic dilated cardiomyopathy. Results indicate that this method should not be recognized as a valve repair, but ventricular repair procedure also.
No takes yet. Share an insight, caveat, or question.
Jonjev et al. (2007) conducted a cohort in Ischemic dilated cardiomyopathy (n=226). Reductive annuloplasty of double (mitral and tricuspid) orifices at the time of coronary artery bypass grafting was evaluated on Postoperative 30-day mortality. Reductive annuloplasty of mitral and tricuspid valves during CABG in patients with ischemic dilated cardiomyopathy resulted in a 30-day mortality of 7.5% and a 10-year survival rate of 38.05%.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: